Bayer secures FDA approval for two MRI contrast agents as US glyphosate lawsuit hurdle is cleared

Bayer received FDA approval for two magnetic‑resonance‑imaging contrast agents—Ambelvist and Gadoquatrane—strengthening its diagnostic pipeline. The approvals are expected to support the company's long‑term revenue prospects, though the share price fell about 1% after earlier sentiment pressure.

In the United States, a federal judge dismissed an effort to move the proposed $7.25 billion glyphosate class‑action settlement to a federal court, sending the case back to a Missouri district court. The decision removed a procedural obstacle and lifted Bayer’s stock by roughly five percent. The company said the ruling provides needed clarity to continue the settlement process, which aims to resolve thousands of lawsuits over alleged cancer risks linked to its Roundup herbicide.

Together, the regulatory win and the litigation development highlight Bayer’s simultaneous focus on expanding its medical portfolio while navigating costly legal challenges.